Published in Eur J Biochem on December 01, 2002
Inhibition of HMGcoA reductase by atorvastatin prevents and reverses MYC-induced lymphomagenesis. Blood (2007) 1.27
miR-146a promotes the initiation and progression of melanoma by activating Notch signaling. Elife (2014) 1.02
Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy. Invest New Drugs (2014) 0.94
Exploring metallodrug-protein interactions by mass spectrometry: comparisons between platinum coordination complexes and an organometallic ruthenium compound. J Biol Inorg Chem (2009) 0.88
Biological role of adduct formation of the ruthenium(III) complex NAMI-A with serum albumin and serum transferrin. Invest New Drugs (2003) 0.88
Antiangiogenic properties of selected ruthenium(III) complexes that are nitric oxide scavengers. Br J Cancer (2003) 0.87
Pathophysiology of tumor neovascularization. Vasc Health Risk Manag (2005) 0.86
Ruthenium anticancer drugs and proteins: a study of the interactions of the ruthenium(III) complex imidazolium trans-[tetrachloro(dimethyl sulfoxide)(imidazole)ruthenate(III)] with hen egg white lysozyme and horse heart cytochrome c. J Biol Inorg Chem (2007) 0.80
MiR-27a-3p functions as an oncogene in gastric cancer by targeting BTG2. Oncotarget (2016) 0.80
Hypoxia-selective inhibition of angiogenesis development by NAMI-A analogues. Biometals (2016) 0.75
Pharmacological Activities of Ruthenium Complexes Related to Their NO Scavenging Properties. Int J Mol Sci (2016) 0.75
Direct estradiol and diethylstilbestrol actions on early- versus late-stage prostate cancer cells. Prostate (2014) 0.75
The antimetastatic drug NAMI-A potentiates the phenylephrine-induced contraction of aortic smooth muscle cells and induces a transient increase in systolic blood pressure. J Biol Inorg Chem (2015) 0.75
Dichloroacetate induces apoptosis in endometrial cancer cells. Gynecol Oncol (2008) 1.79
Term Amniotic membrane is a high throughput source for multipotent Mesenchymal Stem Cells with the ability to differentiate into endothelial cells in vitro. BMC Dev Biol (2007) 1.71
Genetic deletion of Rac1 GTPase reveals its critical role in actin stress fiber formation and focal adhesion complex assembly. J Biol Chem (2006) 1.66
Genetic basis of pulmonary arterial hypertension: current understanding and future directions. J Am Coll Cardiol (2004) 1.53
A review on usnic acid, an interesting natural compound. Naturwissenschaften (2002) 1.43
In vitro and in vivo evaluation of ruthenium(II)-arene PTA complexes. J Med Chem (2005) 1.35
Cdc42 GTPase-activating protein deficiency promotes genomic instability and premature aging-like phenotypes. Proc Natl Acad Sci U S A (2007) 1.25
Metal-based antitumour drugs in the post genomic era. Dalton Trans (2006) 1.24
RhoA GTPase is dispensable for actomyosin regulation but is essential for mitosis in primary mouse embryonic fibroblasts. J Biol Chem (2011) 1.23
Ruthenium antimetastatic agents. Curr Top Med Chem (2004) 1.20
Modulation of the metastatic progression of breast cancer with an organometallic ruthenium compound. Int J Oncol (2008) 1.18
Cdc42 is an antihypertrophic molecular switch in the mouse heart. J Clin Invest (2009) 1.08
Future perspectives for the treatment of pulmonary arterial hypertension. J Am Coll Cardiol (2009) 1.08
Novel docetaxel-loaded nanoparticles based on poly(lactide-co-caprolactone) and poly(lactide-co-glycolide-co-caprolactone) for prostate cancer treatment: formulation, characterization, and cytotoxicity studies. Nanoscale Res Lett (2011) 1.08
Radiofrequency energy loop primes cardiac, neuronal, and skeletal muscle differentiation in mouse embryonic stem cells: a new tool for improving tissue regeneration. Cell Transplant (2011) 1.06
Structure-dependent in vitro cytotoxicity of the isomeric complexes [Ru(L)2Cl2] (L= o-tolylazopyridine and 4-methyl-2-phenylazopyridine) in comparison to [Ru(azpy)2Cl2]. J Biol Inorg Chem (2004) 1.05
Ruthenium anticancer compounds: myths and realities of the emerging metal-based drugs. Dalton Trans (2011) 1.05
Targeted biocompatible nanoparticles for the delivery of (-)-epigallocatechin 3-gallate to prostate cancer cells. J Med Chem (2011) 1.05
A new nonenzymatic method and device to obtain a fat tissue derivative highly enriched in pericyte-like elements by mild mechanical forces from human lipoaspirates. Cell Transplant (2012) 1.03
Half-sandwich Ru II[9]aneS3 complexes structurally similar to antitumor-active organometallic piano-stool compounds: preparation, structural characterization and in vitro cytotoxic activity. J Inorg Biochem (2008) 1.02
NAADP-induced Ca(2+ signaling in response to endothelin is via the receptor subtype B and requires the integrity of lipid rafts/caveolae. J Cell Physiol (2008) 1.00
Development of polymeric microbubbles targeted to prostate-specific membrane antigen as prototype of novel ultrasound contrast agents. Mol Pharm (2011) 0.98
Akt downregulation by flavin oxidase-induced ROS generation mediates dose-dependent endothelial cell damage elicited by natural antioxidants. Toxicol Sci (2009) 0.98
Mild exercise training, cardioprotection and stress genes profile. Eur J Appl Physiol (2007) 0.98
Analysis of candidate genes through a proteomics-based approach in primary cell lines from malignant melanomas and their metastases. Melanoma Res (2005) 0.97
Metal-based inhibition of poly(ADP-ribose) polymerase--the guardian angel of DNA. J Med Chem (2011) 0.97
Radio electric conveyed fields directly reprogram human dermal skin fibroblasts toward cardiac, neuronal, and skeletal muscle-like lineages. Cell Transplant (2012) 0.97
Ruthenium-based NAMI-A type complexes with in vivo selective metastasis reduction and in vitro invasion inhibition unrelated to cell cytotoxicity. Int J Oncol (2002) 0.95
Mesenchymal stem cells and islet cotransplantation in diabetic rats: improved islet graft revascularization and function by human adipose tissue-derived stem cells preconditioned with natural molecules. Cell Transplant (2012) 0.94
PKC/Raf/MEK/ERK signaling pathway modulates native-LDL-induced E2F-1 gene expression and endothelial cell proliferation. Cardiovasc Res (2003) 0.94
Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy. Invest New Drugs (2014) 0.94
Is taurine beneficial in reducing risk factors for diabetes mellitus? Neurochem Res (2004) 0.92
Induction of caspase 8 and reactive oxygen species by ruthenium-derived anticancer compounds with improved water solubility and cytotoxicity. Biochem Pharmacol (2012) 0.91
Mesenchymal stem cells in renal function recovery after acute kidney injury: use of a differentiating agent in a rat model. Cell Transplant (2010) 0.90
Development of ruthenium antitumor drugs that overcome multidrug resistance mechanisms. J Med Chem (2007) 0.90
Control of autocrine and paracrine myocardial signals: an emerging therapeutic strategy in heart failure. Heart Fail Rev (2010) 0.90
The anti-metastatic agent imidazolium trans-imidazoledimethylsulfoxide-tetrachlororuthenate induces endothelial cell apoptosis by inhibiting the mitogen-activated protein kinase/extracellular signal-regulated kinase signaling pathway. Arch Biochem Biophys (2002) 0.89
Inhibition of hepatocellular carcinomas in vitro and hepatic metastases in vivo in mice by the histone deacetylase inhibitor HA-But. Clin Cancer Res (2004) 0.89
Hyaluronan esters drive Smad gene expression and signaling enhancing cardiogenesis in mouse embryonic and human mesenchymal stem cells. PLoS One (2010) 0.87
Radioelectric asymmetric conveyed fields and human adipose-derived stem cells obtained with a nonenzymatic method and device: a novel approach to multipotency. Cell Transplant (2013) 0.87
Placental stem cells pre-treated with a hyaluronan mixed ester of butyric and retinoic acid to cure infarcted pig hearts: a multimodal study. Cardiovasc Res (2011) 0.87
Apricot melanoidins prevent oxidative endothelial cell death by counteracting mitochondrial oxidation and membrane depolarization. PLoS One (2012) 0.86
Regenerative treatment using a radioelectric asymmetric conveyor as a novel tool in antiaging medicine: an in vitro beta-galactosidase study. Clin Interv Aging (2012) 0.86
Anti-senescence efficacy of radio-electric asymmetric conveyer technology. Age (Dordr) (2013) 0.86
Effects of regenerative radioelectric asymmetric conveyer treatment on human normal and osteoarthritic chondrocytes exposed to IL-1β. A biochemical and morphological study. Clin Interv Aging (2013) 0.86
Analysis of the cytotoxicity of synthetic antimicrobial peptides on mouse leucocytes: implications for systemic use. J Antimicrob Chemother (2002) 0.86
Tuning the hydrophobicity of ruthenium(II)-arene (RAPTA) drugs to modify uptake, biomolecular interactions and efficacy. Dalton Trans (2007) 0.86
Linking the future of anticancer metal-complexes to the therapy of tumour metastases. Chem Soc Rev (2015) 0.85
Sodium butyrate inhibits platelet-derived growth factor-induced proliferation and migration in pulmonary artery smooth muscle cells through Akt inhibition. FEBS J (2013) 0.85
Ruthenium-porphyrin conjugates with cytotoxic and phototoxic antitumor activity. J Med Chem (2010) 0.85
Synthesis, characterization, and in vitro evaluation of novel ruthenium(II) eta6-arene imidazole complexes. J Med Chem (2006) 0.84
Triazine dyes are agonists of the NAADP receptor. Br J Pharmacol (2004) 0.83
S-homocysteinylated LDL apolipoprotein B adversely affects human endothelial cells in vitro. Atherosclerosis (2009) 0.83
The hydrolysis of the anti-cancer ruthenium complex NAMI-A affects its DNA binding and antimetastatic activity: an NMR evaluation. J Inorg Biochem (2004) 0.83
Hyaluronan mixed esters of butyric and retinoic acid affording myocardial survival and repair without stem cell transplantation. J Biol Chem (2010) 0.83
Ruthenium(III) dimethyl sulfoxide pyridinehydroxamic acid complexes as potential antimetastatic agents: synthesis, characterisation and in vitro pharmacological evaluation. J Biol Inorg Chem (2008) 0.83
Platinum(II) complexes with antitumoral/antiviral aromatic heterocycles: effect of glutathione upon in vitro cell growth inhibition. J Med Chem (2005) 0.82
Hyaluronic-acid butyric esters as promising antineoplastic agents in human lung carcinoma: a preclinical study. Invest New Drugs (2004) 0.82
Amniotic fluid stem cells morph into a cardiovascular lineage: analysis of a chemically induced cardiac and vascular commitment. Drug Des Devel Ther (2013) 0.82
Preclinical combination therapy of the investigational drug NAMI-A(+) with doxorubicin for mammary cancer. Invest New Drugs (2014) 0.81
Temperature dependence of chaperone-like activity and oligomeric state of alphaB-crystallin. Biochim Biophys Acta (2006) 0.81
Profiling the molecular mechanism of fullerene cytotoxicity on tumor cells by RNA-seq. Toxicology (2013) 0.81
Ruthenium anticancer drugs. Met Ions Biol Syst (2004) 0.80
Plasma methionine determination by capillary electrophoresis-UV assay: application on patients affected by retinal venous occlusive disease. Anal Biochem (2007) 0.80
Acute variations in homocysteine levels are related to creatine changes induced by physical activity. Clin Nutr (2007) 0.80
Highly sensitive simultaneous detection of cultured cellular thiols by laser induced fluorescence-capillary electrophoresis. Electrophoresis (2005) 0.80
Antiviral properties and cytotoxic activity of platinum(II) complexes with 1,10-phenanthrolines and acyclovir or penciclovir. J Inorg Biochem (2004) 0.80
Molecular structure, solution chemistry and biological properties of the novel [ImH][trans-IrCl(4)(Im)(DMSO)], (I) and of the orange form of [(DMSO)(2)H][trans-IrCl(4)(DMSO)(2)], (II), complexes. J Inorg Biochem (2003) 0.79
Rosuvastatin elicits KDR-dependent vasculogenic response of human placental stem cells through PI3K/AKT pathway. Pharmacol Res (2011) 0.79
Forced myocardin expression primes cardiac and smooth muscle transcription patterning in human mesenchymal stem cells. Cardiovasc Res (2005) 0.79
Distinct effects of dinuclear ruthenium(III) complexes on cell proliferation and on cell cycle regulation in human and murine tumor cell lines. J Pharmacol Exp Ther (2003) 0.79
Electrochemical measurements confirm the preferential bonding of the antimetastatic complex [ImH][RuCl(4)(DMSO)(Im)] (NAMI-A) with proteins and the weak interaction with nucleobases. J Inorg Biochem (2004) 0.79
Different redox response elicited by naturally occurring antioxidants in human endothelial cells. Open Biochem J (2013) 0.78
Solution, solid state and biological characterization of ruthenium(III)-DMSO complexes with purine base derivatives. J Inorg Biochem (2004) 0.78
Tumour cell uptake of the metastasis inhibitor ruthenium complex NAMI-A and its in vitro effects on KB cells. Cancer Chemother Pharmacol (2002) 0.78
Photostability profiles of the experimental antimetastatic ruthenium complex NAMI-A. J Pharm Biomed Anal (2002) 0.77
TGFbeta1 regulation and collagen-release-independent connective tissue re-modelling by the ruthenium complex NAMI-A in solid tumours. J Inorg Biochem (2004) 0.77
RNA-seq analysis of the whole transcriptome of MDA-MB-231 mammary carcinoma cells exposed to the antimetastatic drug NAMI-A. Metallomics (2015) 0.77
Prune melanoidins protect against oxidative stress and endothelial cell death. Front Biosci (Elite Ed) (2011) 0.77
Effect of low doses of ethanol on platelet function in long-life abstainers and moderate-wine drinkers. Life Sci (2003) 0.77
Optimization of the principal parameters for the ultrarapid electrophoretic separation of reduced and oxidized glutathione by capillary electrophoresis. J Chromatogr A (2003) 0.77
The Oxidative State of LDL is the Major Determinant of Anti/Prooxidant Effect of Coffee on Cu Catalysed Peroxidation. Open Biochem J (2011) 0.77
Neonatal taurine administration modifies metabolic programming in male mice. Early Hum Dev (2007) 0.77
Evolving antithrombotic strategies in patients with atrial fibrillation undergoing percutaneous coronary intervention: results from a survey among US cardiologists. Clin Cardiol (2014) 0.77
Ultrarapid capillary electrophoresis method for the determination of reduced and oxidized glutathione in red blood cells. Electrophoresis (2002) 0.77
Inhibition of human pancreatic cell line MIA PaCa2 proliferation by HA-But, a hyaluronic butyric ester: a preliminary report. Pancreas (2008) 0.77
Intratumoral NAMI-A treatment triggers metastasis reduction, which correlates to CD44 regulation and tumor infiltrating lymphocyte recruitment. J Pharmacol Exp Ther (2004) 0.77
Cocultures of metastatic and host immune cells: selective effects of NAMI-A for tumor cells. Cancer Immunol Immunother (2004) 0.77
CDK1 hyperphosphorylation maintenance drives the time-course of G2-M cell cycle arrest after short treatment with NAMI-A in Kb cells. Anticancer Agents Med Chem (2012) 0.76